South San Francisco, CA, United States of America

Sarah Bronner

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 10.1

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
7 patents (USPTO):

Title: Sarah Bronner: Innovator in Therapeutic Compounds

Introduction

Sarah Bronner is a prominent inventor based in South San Francisco, CA. She has made significant contributions to the field of therapeutic compounds, holding a total of seven patents. Her work focuses on innovative solutions for treating disorders related to cytokines and other inflammatory processes.

Latest Patents

Among her latest patents is a groundbreaking invention titled "Sulfonimidamide compounds as inhibitors of interleukin-1 activity." This patent relates to novel sulfonimidamide compounds and their application in treating disorders responsive to modulation of cytokines such as IL-1β and IL-18. Additionally, she has developed a patent for "Therapeutic compounds and uses thereof," which involves a specific compound formula and its pharmaceutical applications. These compounds are designed to inhibit CBP and/or EP300, providing new avenues for treatment of various disorders.

Career Highlights

Throughout her career, Sarah has worked with notable companies such as Genentech, Inc. and Constellation Pharmaceuticals, Inc. Her experience in these organizations has allowed her to refine her expertise in the development of therapeutic compounds and their applications in medicine.

Collaborations

Sarah has collaborated with esteemed colleagues, including Patrick Cyr and Kwong Wah Lai. These partnerships have contributed to her innovative research and the successful development of her patents.

Conclusion

Sarah Bronner is a trailblazer in the field of therapeutic innovations, with a strong portfolio of patents that address critical health issues. Her work continues to impact the medical community positively, paving the way for future advancements in treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…